Shots:

• The sNDA application is based on results of P-III iLLUMINATE (PCYC-1130) trial assessing Imbruvica (420) + Obinutuzumab (1000) vs chlorambucil (Days 1 & 15) + obinutuzumab (1000) over 6 cycles in patients with 1L CLL/SLL
• The iLLUMINATE study demonstrated 1EP as PFS- which showed longer PFS rate for Imbruvica + Obinutuzumab vs chlorambucil + obinutuzumab- as per IRC
• Imbruvica is novel PO BTKi qd therapy and has received nine FDA approvals across six diseases. The combination with anti-CD20 will be a novel CT-free combination if approved by the FDA for 1L CLL treatment

Ref: AbbVie | Image: Reeves Recruiting